



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

## Complete If Known

Application Number	10/716,929
Filing Date	11/19/03
First Named Inventor	REKHA BANSAL
Art Unit	1644
Examiner Name	VanderVegt

Attorney Docket Number

NMT-NPU-1103-01

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue-number(s), publisher, city and/or country where published.	T <sup>2</sup>
/PVI	1	CLARDY, C.W. COMPLEMENT ACTIVATION BY WHOLE ENDOTOXIN IS BLOCKED BY A MONOCLONAL ANTIBODY TO FACTOR B. <u>INFECTION AND IMMUNITY</u> 1994, 62(10), 4599-4555	
	2	MATSUMOTO, M. ET AL., ABROGATION OF THE ALTERNATIVE COMPLEMENT PATHWAY BY TARGETED DELETION OF MURINE FACTOR B. <u>PROC. NATL. ACAD. SCI. USA</u> . 1997, 94, 8720-8725	
	3	HOURCADE, D.E. ET AL. ANALYSIS OF THE SHORT CONSENSUS REPEATS OF HUMAN COMPLEMENT FACTOR B BY SITE-DIRECTED MUTAGENESIS. <u>J. BIOL. CHEM.</u> 1995, 270(34), 19716-19722	
	4	HENSLEY P. ET AL. THE EFFECTS OF METAL IONS AND TEMPERATURE ON THE INTERACTION OF COBRA VENOM FACTOR AND HUMAN COMPLEMENT FACTOR B. <u>J. BIOL. CHEM.</u> 1986, 261(24), 11038-11044.	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete If Known	
Application Number	10/716,929
Filing Date	11/19/03
First Named Inventor	REKHA BANSAL
Art Unit	1644
Examiner Name	VanderVegt
Attorney Docket Number	NMT-NPV-1103-01

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
IPVI	5	HOURCADE, D.E. ET AL. MUTATIONS OF THE TYPE A DOMAIN OF COMPLEMENT FACTOR B THAT PROMOTE HIGH-AFFITY C3b-BINDING. <u>THE JOURNAL OF IMMUNOLOGY</u> 1999, 162, 2906-2911.	
IPVI	6	HORIUCHI, T. ET AL. HUMAN COMPLEMENT FACTOR B: cDNA CLONING, NUCLEOTIDE SEQUENCING, PHENOTYPIC CONVERSION, BY SITE-DIRECTED MUTAGENESIS AND EXPRESSION. <u>MOLECULAR IMMUNOLOGY</u> 1993, 30(17), 1587-1592	

Examiner Signature	/F. Pierre VanderVegt/	Date Considered	07/03/2007
--------------------	------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.